MedTrace Logo

WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC

NCT04644289 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-10-03

No results posted yet for this study

Summary

This is a multi-center, prospective, open-label, phase II trial. Patients with suspected advanced ovarian cancer planned to undergo diagnostic laparoscopy for histologic confirmation and evaluation of disease spread will be registered into the trial after providing a 1st written informed consent.

Conditions

  • Epithelial Ovarian Cancer

Interventions

DRUG

olaparib

Olaparib tablets are administrated orally 300 mg twice daily.

DRUG

durvalumab

Durvalumab is administered 1500mg iv as a single dose prior to surgery (corresponding to 1 single cycle) .

Sponsors & Collaborators

  • AGO Research GmbH

    lead INDUSTRY

Principal Investigators

  • Frederik Marmé, MD · Universitätsklinikum Mannheim, Frauenklinik

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-05
Primary Completion
2028-01-31
Completion
2028-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04644289 on ClinicalTrials.gov